DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
T• T••••••••• I••
Drug Discovery & Developmentgroup grade Aon a schedule nowsponsor unattributed
Principal held
unknown
sum of BDC pieces, a lower bound
Fair value
$3.4M
n/a on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
8
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
unstated
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
4
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Sep 30, 2024 | at least $125M | 100c | S+550 bp | Aug 1, 2029 | 8 |
Equity pieces beside the debt: warrants ($3.4M fair value, 1 BDC)
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | warrants equity W••••••, 12/30/2021, C••••• S•••• | n/a | $3.4M 471c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2026 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Jun 30, 2025 | 1 | $0 | $0 | n/a | 0 |
| Mar 31, 2025 | 1 | $0 | $0 | n/a | 0 |
| Dec 31, 2024 | 1 | $0 | $0 | n/a | 0 |
| Sep 30, 2024 | 8 | $125M | $124M | 100c | 0 |
| Jun 30, 2024 | 1 | $66.5M | $69.6M | 103c | 1 |
| Mar 31, 2024 | 1 | $66.1M | $68.8M | 103c | 1 |
| Dec 31, 2023 | 1 | $132M | $135M | 102c | 2 |
| Sep 30, 2023 | 1 | $65.4M | $66.7M | 102c | 1 |
| Jun 30, 2023 | 1 | $65.0M | $65.1M | 100c | 1 |
| Mar 31, 2023 | 1 | $64.6M | $64.4M | 100c | 1 |
| Dec 31, 2022 | 1 | $48.0M | $48.6M | 102c | 1 |
What changed
- Maturity extended (observed)Sep 30, 2024
- Facility left every BDC scheduleSep 30, 2024
- Spread changed (observed)Sep 30, 2024
- Lender left a facilitySep 30, 2024
- New lender joined a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- New lender joined a facilitySep 30, 2024
- New lender joined a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- New lender joined a facilitySep 30, 2024
- New lender joined a facilitySep 30, 2024
- New lender joined a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- Lender left a facilitySep 30, 2024
- New lender joined a facilitySep 30, 2024
- Lender left a facilityJun 30, 2024
- Spread changed (observed)Mar 31, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- T• T•••••••••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 8 BDCsderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it